A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
mediaposted on 06.05.2021, 10:57 by Adis journals on behalf of, Doreen Barrett, Sanela Bilic, Yung Chyung, Shaun M. Cote, Ryan Iarrobino, Katherine Kacena, Ashish Kalra, Kimberly Long, George Nomikos, Amy Place, James Gordon Still, Leela Vrishabhendra
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.